Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Will Berinert's US OK for self-administration put Shire's Firazyr on the run?

This article was originally published in Scrip

Executive Summary

With the US FDA granting CSL Behring permission to market its hereditary angioedema (HAE) drug Berinert, a plasma-derived C1 inhibitor replacement product, as a self-administered medicine for acute abdominal, facial or laryngeal swelling attacks, the company may have Shire's Firazyr (icatibant) on the run, although as a subcutaneously administered treatment, the latter may still win out.



Related Companies